Dry and Wet Age-Related Macular Degeneration | Disease Landscape & Forecast | G7 | 2022

The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors: Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis, and Regeneron / Bayer HealthCare / Santen’s Eylea. Roche’s Susvimo (ranibizumab PDS), which launched in November 2021 in the United States, will also continue to attract a small patient share because of its less frequent dosing regimen of once every six months. Additionally, we expect Roche / Chugai’s Vabysmo (faricimab), which launched in the United States in February 2022, in the United Kingdom and Japan in May 2022, and in Germany in October 2022, to continue to see strong uptake, driven by its new MOA and advantageous dosing regimen. Nevertheless, the mainstay anti-VEGF therapies will face competition from the growing number of therapies for wet AMD in the late-phase pipeline, including Regeneron / Bayer’s high-dose aflibercept and biosimilar agents. In contrast to the management of wet AMD, management of dry AMD is limited because no prescription therapies are approved for this large subpopulation. Despite setbacks in the clinical development of some late-phase dry AMD therapies, other agents are progressing, such as Apellis’s pegcetacoplan and Iveric Bio’s Zimura, increasing the likelihood that an effective therapy may emerge as soon as 2023.

Questions answered

• How will the wet AMD treatment algorithm change as new products launch?
• To what extent will novel therapies such as Roche’s ranibizumab PDS and faricimab capitalize on the need for therapies with longer dosing intervals?
• How will market dynamics be impacted by the launch of biosimilars of Lucentis and Eylea?
• How receptive are retinal specialists to novel gene therapy approaches and to emerging therapies for wet AMD and GA?
• What will be the impact of Outlook Therapeutics’ ONS-5010 on Avastin if it launches for wet AMD, particularly in the United States?

Content highlights

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 25 country-specific interviews with thought-leading retinal specialists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Total prevalence of late AMD by country, segmented by GA and wet AMD subpopulations, including diagnosed and drug-treated rates.

Forecast: 10-year, annualized, drug-level sales and patient share of key GA and wet AMD therapies through 2031, segmented by brands / biosimilars and epidemiological subpopulations.

Emerging therapies: Phase III / PR: 7 drugs; Phase II: 12 drugs; coverage of select Phase I products.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.